logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — Adjuvant abemaciclib, a novel practice-changing option in early breast cancer

Adding the CDK4/6 inhibitor to adjuvant hormonal therapy reduces recurrence risk by 25% in a subset.